A5032842440- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Mast cells and histamine
- Breast Cancer Treatment Studies
- Gallbladder and Bile Duct Disorders
- Pancreatic and Hepatic Oncology Research
- Medical Imaging and Pathology Studies
- Cancer, Lipids, and Metabolism
- Brain Metastases and Treatment
- Liver Disease Diagnosis and Treatment
- Renal cell carcinoma treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Colorectal Cancer Treatments and Studies
- Ferroptosis and cancer prognosis
- Protease and Inhibitor Mechanisms
- Immunotherapy and Immune Responses
- Lung Cancer Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
Ospedale San Paolo
2024
ASL Roma
2022
Vita-Salute San Raffaele University
2016
Istituto Tumori Bari
2009-2014
Oncology Group of Southern Italy
2014
University of Bari Aldo Moro
1994-2009
Azienda Ospedaliera di Cosenza
2002-2006
Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Recent years have seen the emergence novel systemic treatments for HCC patients, including immune checkpoint inhibitors (ICIs). Nonetheless, several questions regarding immunotherapy remain unanswered, especially in terms biochemical predictors response.In current paper, we will discuss available evidence predictive biomarkers response to...
Abstract Bone marrow plasma cells and stromal in multiple myeloma (MM) have been shown to be capable of releasing cytokines with angiogenic properties. Plasma can also express adhesion molecules controlling their adhesive interactions endothelial cells. In the present study, we evaluated by immunohistochemistry extent angiogenesis bone of: a) 51 patients active non‐active MM; b) 25 monoclonal gammopathy undetermined significance (MGUS). were investigated flow cytometry for expression LFA‐1,...
Background: Whether the etiology of underlying liver disease represents a prognostic factor in patients with hepatocellular carcinoma (HCC) treated lenvatinib is still matter debate. This study investigates whether viral HCC plays role overall survival (OS). Methods: Data derived from multicenter series 313 between 2019 and 2022 were analyzed. Actuarial estimates computed using Kaplan–Meier method compared log-rank test. We performed an event-based counterfactual mediation analysis to...
Treatment of patients affected by metastatic gastric cancer with low performance status (PS) is a very hard choice. It mandatory to define well-tolerated schedule be employed in these subgroup patients.From June 1999 December 2001, 21 (pts) (> or = 2 ECOG) were treated bimonthly "de Gramont" schedule. was planned perform 6 courses chemotherapy for each patient plus other 2-4 if response had been documented.A total 161 de Gramont administered the pts enrolled. We observed 8 PD (38%), SD 5...
To evaluate the feasibility, safety, and effectiveness of combining segmental pulmonary arterial chemoembolization (SPACE) percutaneous radiofrequency (RF) ablation in patients with unresectable lung neoplasms or resectable who refused surgery to compare local tumor progression (LTP) rate that previous studies RF alone.After institutional review board approval informed consent, 17 primary metastatic cancer were enrolled this prospective study. Between January 2008 February 2011, 20 nodules...
The standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib, a multikinase inhibitor of tumor cell proliferation and angiogenesis. Hyperthermia inhibits angiogenesis promotes apoptosis. Potential synergic antiangiogenic proapoptotic effects represent the rationale combining sorafenib with electro‑hyperthermia (EHY) in HCC. A total 21 patients (median age, 64 years; range, 55‑73 years) HCC were enrolled current study between February 2009 September 2010. EHY was achieved...
Although several molecular markers have been proposed as prognostic of disease progression in Hepatocellular carcinoma (HCC), predictive response to treatment are still unsatisfactory. Here, we propose a genetic polymorphism potential factor poor prognosis HCC patients treated with transcatheter arterial chemoembolization (TACE). In particular, show that the guanosine insertion/deletion promoter region SERPINE1 gene at − 675 bp position, named 4G/4G, predicts cohort 75 undergoing TACE. By...
Metastatic HR+/HER2- breast cancer is commonly treated with CDK4/6 inhibitors in combination endocrine therapy. However, the efficacy and safety of this approach elderly patients (≥70 years) remain unclear, particularly context real-world clinical practice. This study aims to evaluate outcomes tolerability inhibitor treatments fragile population, which often under-represented randomized trials.